Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gassmann

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Nature Reviews. Drug Discovery|December 12, 2022
The significance of blockbusters in the pharmaceutical industryAlexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
The Journal of Product Innovation Management|May 3, 2016
Technologically Reflective Individuals as Enablers of Social InnovationFiona Schweitzer, Christiane Rau, Oliver Gassmann, et al.
Nature Reviews. Drug Discovery|July 5, 2023
Investigating the origins of recent pharmaceutical innovationAlexander Schuhmacher, Markus Hinder, Alexander Dodel, et al.
Drug Discovery Today|January 13, 2025
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Drug Discovery Today|June 20, 2020
The upside of being a digital pharma playerAlexander Schuhmacher, Alexander Gatto, Markus Hinder, et al.
Drug Discovery Today|November 25, 2022
The dominant logic of Big Tech in healthcare and pharmaAlexander Schuhmacher, Naomi Haefner, Katharina Honsberg, et al.
Drug Discovery Today|May 9, 2021
Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligenceAlexander Schuhmacher, Alexander Gatto, Michael Kuss, et al.
Drug Discovery Today|February 3, 2025
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companiesAlexander Schuhmacher, Kyrylo Grinchenko, Oliver Gassmann, et al.
Drug Discovery Today|March 13, 2025
Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291]Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Drug Discovery Today|September 29, 2023
Is the blockbuster imperative broken?Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Nature Reviews. Drug Discovery|December 12, 2022
The significance of blockbusters in the pharmaceutical industryAlexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
The Journal of Product Innovation Management|May 3, 2016
Technologically Reflective Individuals as Enablers of Social InnovationFiona Schweitzer, Christiane Rau, Oliver Gassmann, et al.
Nature Reviews. Drug Discovery|July 5, 2023
Investigating the origins of recent pharmaceutical innovationAlexander Schuhmacher, Markus Hinder, Alexander Dodel, et al.
Drug Discovery Today|January 13, 2025
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Drug Discovery Today|June 20, 2020
The upside of being a digital pharma playerAlexander Schuhmacher, Alexander Gatto, Markus Hinder, et al.
Drug Discovery Today|November 25, 2022
The dominant logic of Big Tech in healthcare and pharmaAlexander Schuhmacher, Naomi Haefner, Katharina Honsberg, et al.
Drug Discovery Today|May 9, 2021
Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligenceAlexander Schuhmacher, Alexander Gatto, Michael Kuss, et al.
Drug Discovery Today|February 3, 2025
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companiesAlexander Schuhmacher, Kyrylo Grinchenko, Oliver Gassmann, et al.
Drug Discovery Today|March 13, 2025
Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291]Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Drug Discovery Today|September 29, 2023
Is the blockbuster imperative broken?Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
Pageof 3